The Analytical Chemistry of Cannabis by Thomas Brian F; ElSohly Mahmoud; & Mahmoud A. ElSohly

Author:Thomas, Brian F; ElSohly, Mahmoud; & Mahmoud A. ElSohly [Thomas, Brian F. & ElSohly, Mahmoud A.]
Language: eng
Format: epub
Publisher: Elsevier Science
Published: 2016-11-15T00:00:00+00:00

References

1. Bedrocan. <http://www.bedrocan.nl/english/home.html>; 2015 Accessed 28.09.15.

2. Potter DJ. Cannabis horticulture. In: Pertwee RG, ed. Handbook of Cannabis. New York, NY: Oxford University Press; 2014;65–88.

3. Hazekamp A, Bastola K, Rashidi H, Bender J, Verpoorte R. Cannabis tea revisited: a systematic evaluation of the cannabinoid composition of cannabis tea. J Ethnopharmacol. 2007;113(1):85–90.

4. Klumpers LE, Beumer TL, van Hasselt JG, et al. Novel Delta(9)-tetrahydrocannabinol formulation Namisol® has beneficial pharmacokinetics and promising pharmacodynamic effects. Br J Clin Pharmacol. 2012;74(1):42–53.

5. Zuardi AW. History of cannabis as a medicine: a review. Rev Bras Psiquiatr. 2006;28:153–157.

6. Potter DJ. A review of the cultivation and processing of cannabis (Cannabis sativa L.) for production of prescription medicines in the UK. Drug Test Anal. 2014;6(1–2):31–38.

7. Grotenhermen F. Cannabinoids for therapeutic use. Am J Drug Deliv. 2004;2(4):229–240.

8. Duchi S, Ovadia H, Touitou E. Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis. J Neuroimmunol. 2013;258(1–2):32–40.

9. Al-Ghananeem AM, Malkawi AH, Crooks PA. Bioavailability of Delta(9)-tetrahydrocannabinol following intranasal administration of a mucoadhesive gel spray delivery system in conscious rabbits. Drug Dev Ind Pharm. 2011;37(3):329–334.

10. Paudel KS, Hammell DC, Agu RU, Valiveti S, Stinchcomb AL. Cannabidiol bioavailability after nasal and transdermal application: effect of permeation enhancers. Drug Dev Ind Pharm. 2010;36(9):1088–1097.

11. Valiveti S, Agu RU, Hammell DC, et al. Intranasal absorption of Delta(9)-tetrahydrocannabinol and WIN55,212-2 mesylate in rats. Eur J Pharm Biopharm. 2007;65(2):247–252.

12. Cichewicz DL, Welch SP, Smith FL. Enhancement of transdermal fentanyl and buprenorphine antinociception by transdermal delta9-tetrahydrocannabinol. Eur J Pharmacol. 2005;525(1–3):74–82.

13. Liput DJ, Hammell DC, Stinchcomb AL, Nixon K. Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder. Pharmacol Biochem Behav. 2013;111:120–127.

14. Valiveti S, Hammell DC, Earles DC, Stinchcomb AL. In vitro/in vivo correlation studies for transdermal delta 8-THC development. J Pharm Sci. 2004;93(5):1154–1164.

15. Fischer KM, Ward DA, Hendrix DV. Effects of a topically applied 2% delta-9-tetrahydrocannabinol ophthalmic solution on intraocular pressure and aqueous humor flow rate in clinically normal dogs. Am J Vet Res. 2013;74(2):275–280.

16. Merritt JC, Perry DD, Russell DN, Jones BF. Topical delta 9-tetrahydrocannabinol and aqueous dynamics in glaucoma. J Clin Pharmacol. 1981;21(8–9 suppl):467S–471S.

17. Green K, Roth M. Ocular effects of topical administration of delta 9-tetrahydrocannabinol in man. Arch Ophthalmol (Chicago, Ill.: 1960). 1982;100(2):265–267.

18. Naveh N, Weissman C, Muchtar S, Benita S, Mechoulam R. A submicron emulsion of HU-211, a synthetic cannabinoid, reduces intraocular pressure in rabbits. Graefes Arch Clin Exp Ophthalmol. 2000;238(4):334–338.

19. Merritt JC, Olsen JL, Armstrong JR, McKinnon SM. Topical delta 9-tetrahydrocannabinol in hypertensive glaucomas. J Pharm Pharmacol. 1981;33(1):40–41.

20. Hippalgaonkar K, Gul W, ElSohly MA, Repka MA, Majumdar S. Enhanced solubility, stability, and transcorneal permeability of delta-8-tetrahydrocannabinol in the presence of cyclodextrins. AAPS PharmSciTech. 2011;12(2):723–731.

21. Green KE, Kearse CE. Ocular penetration of topical Delta9-tetrahydrocannabinol from rabbit corneal or cul-de-sac application site. Curr Eye Res. 2000;21(1):566–570.

22. Hingorani T, Gul W, Elsohly M, Repka MA, Majumdar S. Effect of ion pairing on in vitro transcorneal permeability of a Delta(9)-tetrahydrocannabinol prodrug: potential in glaucoma therapy. J Pharm Sci. 2012;101(2):616–626.

23. Kearse EC, Green K. Effect of vehicle upon in vitro transcorneal permeability and intracorneal content of Delta9-tetrahydrocannabinol.

Download

Copyright Disclaimer:
This site does not store any files on its server. We only index and link to content provided by other sites. Please contact the content providers to delete copyright contents if any and email us, we'll remove relevant links or contents immediately.